Concinnity Genetics (IBioIC award winner)
We want to solve the problem of off-target effects in gene therapies. Side effects are a major problem and can often be caused by the therapy being active in the wrong tissue. This can result in clinical halts and failures, costing time and money and preventing many gene therapies from getting to market. With our unique AI technology, we aim to build gene control systems that ensure the gene therapy is active only in the right place at the right time, accelerating the development of gene therapies and increasing their success in clinical trials.